Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
HZNP Horizon Therapeutics Public Limited Company daily Stock Chart
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Healthcare | Drugs - Generic | Ireland
financial highlights | statements
Index- P/E346.15 EPS (ttm)0.08 Insider Own0.90% Shs Outstand187.95M Perf Week-0.52%
Market Cap5.07B Forward P/E13.39 EPS next Y2.02 Insider Trans-3.15% Shs Float182.62M Perf Month9.62%
Income12.90M PEG21.11 EPS next Q0.50 Inst Own93.90% Short Float2.99% Perf Quarter4.53%
Sales1.26B P/S4.01 EPS this Y77.00% Inst Trans2.65% Short Ratio2.68 Perf Half Y16.53%
Book/sh8.21 P/B3.29 EPS next Y11.88% ROA2.00% Target Price32.90 Perf Year36.50%
Cash/sh4.61 P/C5.86 EPS next 5Y16.40% ROE6.10% 52W Range16.56 - 29.44 Perf YTD38.18%
Dividend- P/FCF15.37 EPS past 5Y22.10% ROI0.30% 52W High-8.29% Beta0.77
Dividend %- Quick Ratio2.10 Sales past 5Y74.80% Gross Margin68.80% 52W Low63.04% ATR0.90
Employees300 Current Ratio2.20 Sales Q/Q5.90% Oper. Margin10.60% RSI (14)62.54 Volatility3.18% 3.49%
OptionableYes Debt/Eq0.90 EPS Q/Q86.10% Profit Margin6.20% Rel Volume0.73 Prev Close26.84
ShortableYes LT Debt/Eq0.90 EarningsAug 07 BMO Payout0.00% Avg Volume2.03M Price27.00
Recom1.90 SMA207.44% SMA5010.77% SMA20014.33% Volume1,480,810 Change0.60%
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Oct-31-16Reiterated Mizuho Buy $33 → $29
Sep-13-16Reiterated Mizuho Buy $30 → $33
Jul-11-16Upgrade Morgan Stanley Underweight → Equal-Weight $24
Jun-06-16Initiated Goldman Buy $24
May-10-16Reiterated Mizuho Buy $25 → $24
Aug-14-19 10:47AM  Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade Benzinga
08:00AM  Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis Community Website Business Wire
Aug-13-19 11:24AM  Canadian drug price regulator may be flexible on rare diseases Reuters
Aug-12-19 07:15PM  Horizon Therapeutics Plc (HZNP) EVP, Corporate Affairs, CCO Geoffrey M. ... GuruFocus.com
Aug-08-19 10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
Aug-07-19 04:31PM  Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses Investor's Business Daily +12.01%
03:23PM  Horizon Pharma PLC (HZNP) Q2 2019 Earnings Call Transcript Motley Fool
08:45AM  Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates Zacks
07:00AM  Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases FullYear 2019 Net Sales and Adjusted EBITDA Guidance Business Wire
Aug-06-19 10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
09:00AM  Which Pharmaceutical Stocks Are Outperforming All Other Stocks? Investor's Business Daily
Jul-31-19 10:36AM  Earnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to Decline Zacks
Jul-25-19 08:00AM  Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy Business Wire
Jul-19-19 09:41AM  Horizon's NDA for Procysbi New Dosage Form Accepted by FDA Zacks
07:19AM  Is Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) A Financially Sound Company? Simply Wall St.
Jul-18-19 09:00AM  Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets Business Wire
Jul-16-19 08:00AM  Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019 Business Wire
Jul-11-19 04:45PM  Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes Business Wire
09:05AM  Horizon Therapeutics Files BLA to FDA for Eye Disease Drug Zacks
Jul-10-19 07:30AM  Horizon Therapeutics plc Announces Proposed Private Offering of Senior Notes Business Wire
07:00AM  Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED) Business Wire
Jun-27-19 09:54AM  Eyes on Graves Initiative Urges Action for People with Graves Disease and Thyroid Eye Disease Business Wire
Jun-23-19 10:19AM  Is There An Opportunity With Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) 50% Undervaluation? Simply Wall St.
Jun-21-19 01:03PM  Heres What Hedge Funds Think About Horizon Therapeutics Public Limited Company (HZNP) Insider Monkey
Jun-20-19 08:00AM  Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy Business Wire
Jun-12-19 08:00AM  Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019 Business Wire
Jun-08-19 09:29AM  How Should Investors Feel About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Pay? Simply Wall St.
Jun-04-19 08:00AM  Horizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference Business Wire +5.19%
May-30-19 07:56PM  Edited Transcript of HZNP earnings conference call or presentation 8-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-29-19 08:00AM  Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program Business Wire
May-21-19 01:30PM  Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE Business Wire
May-16-19 08:00AM  Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout Business Wire
May-12-19 03:30AM  Market Weekly Review: China Trade Dispute Hits Stocks TipRanks
May-09-19 06:17PM  Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates Zacks
08:00AM  Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary Business Wire
May-08-19 04:17PM  Top-Rated Pharma Stock Nears Breakout After Earnings Trounce Views Investor's Business Daily
03:00PM  Here's How Horizon Therapeutics Blew Past Wall Street Estimates in Q1 Motley Fool
01:23PM  Horizon Pharma PLC (HZNP) Q1 2019 Earnings Call Transcript Motley Fool
11:19AM  Top-Rated Pharma Stock Nears Breakout After Earnings Trounce Views Investor's Business Daily
08:25AM  Horizon Pharma (HZNP) Q1 Earnings and Revenues Top Estimates Zacks
07:19AM  Horizon Pharma: 1Q Earnings Snapshot Associated Press
07:04AM  Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases FullYear 2019 Net Sales and Adjusted EBITDA Guidance Business Wire
07:00AM  RPT In Canada, a little-known drug regulator shows its teeth Reuters
03:16AM  In Canada, a little-known drug regulator shows its teeth Reuters
01:13AM  In Canada, a little-known drug regulator shows its teeth Reuters
May-07-19 04:54PM  What's in Store for Axsome (AXSM) This Earnings Season? Zacks
04:48PM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
10:53AM  Guardant Health (GH) to Report Q1 Earnings: What's in Store? Zacks
10:47AM  Proteostasis (PTI) to Post Q1 Earnings: What's in Store? Zacks
09:35AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
07:53AM  What's in Cards for Cumberland (CPIX) This Earnings Season? Zacks
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
03:06PM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
01:32PM  Which Pharmaceutical Stocks Are Outperforming All Other Stocks? Investor's Business Daily
11:54AM  Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up? Zacks
11:42AM  Cronos (CRON) to Report Q1 Earnings: What's in the Cards? Zacks
09:38AM  What's in the Cards for Corbus (CRBP) This Earnings Season? Zacks
08:00AM  Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-03-19 05:22PM  Mylan (MYL) to Report Q1 Earnings: What's in the Offing? Zacks
10:32AM  What's in Store for Sorrento (SRNE) This Earnings Season? Zacks
May-02-19 04:57PM  Regeneron (REGN) to Report Q1 Earnings: What's in Store? Zacks
10:58AM  PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store? Zacks
10:11AM  What's in Store for BioDelivery (BDSI) This Earnings Season? Zacks
10:02AM  What's in the Cards for AEterna (AEZS) This Earnings Season? Zacks
May-01-19 06:07PM  Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings? Zacks
10:32AM  Horizon Pharma (HZNP) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:28AM  What's in the Cards for Novavax (NVAX) This Earnings Season? Zacks
Apr-30-19 10:02AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Apr-29-19 01:36PM  With New Eye Drug, Horizon Could Secure Long-Term Stability GuruFocus.com
08:25AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Apr-26-19 02:00PM  New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED) Business Wire
Apr-25-19 04:36PM  Were Hedge Funds Right About Flocking Into Horizon Pharma plc (HZNP) ? Insider Monkey
Apr-16-19 02:04PM  Recordati to seek Canadian approval for kidney disease drug Reuters
08:00AM  Horizon Pharma plc and Gift of Adoption Announce a New Fund to Facilitate Global Adoptions of Children with Rare Diseases Business Wire
Apr-12-19 08:00AM  Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress Business Wire
Apr-11-19 04:45PM  Horizon Pharma plc Named One of the 2019 Best Workplaces in Health Care and Biopharma by FORTUNE and Great Place to Work® Business Wire
Apr-10-19 10:10AM  Why the Earnings Surprise Streak Could Continue for Horizon Pharma (HZNP) Zacks
Apr-09-19 04:05PM  Horizon Pharma plc to Release First-Quarter 2019 Financial Results and Host Webcast on May 8, 2019 Business Wire
10:55AM  Should You Be Worried About Insider Transactions At Horizon Pharma plc (NASDAQ:HZNP)? Simply Wall St.
Apr-04-19 04:05PM  Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-21-19 12:06AM  Edited Transcript of HZNP earnings conference call or presentation 27-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-18-19 08:00AM  Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy Business Wire
Mar-11-19 04:30PM  Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-08-19 04:35PM  Why This Top-Ranked Pharma Grabbed An Upgrade Despite DOJ Probe Investor's Business Daily
Mar-06-19 10:00PM  Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares Business Wire -6.39%
04:09PM  No. 1 Pharma Stock Dives As DOJ Investigates Potential Kickbacks Investor's Business Daily
07:41AM  Dow Jones Futures: Nio, Qutoutiao IPOs Lead 5 Key Stocks Moving Investor's Business Daily
07:39AM  The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split Benzinga
Mar-05-19 08:10AM  Analysis: Positioning to Benefit within The Goodyear Tire & Rubber, Cars, Tutor Perini, CVS Health, VMware, and Horizon Pharma Public Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-04-19 04:10PM  Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares Business Wire
09:00AM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
Mar-02-19 10:00AM  Celebrating the Greatness of Individual Traders TheStreet.com
Mar-01-19 05:50PM  Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
09:30AM  Company News For Mar 1, 2019 Zacks
08:50AM  The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis Benzinga
08:00AM  Why These Pharma ETFs Rallied on Thursday Zacks
07:37AM  3 Big Stock Charts for Friday: Eli Lilly, Centene and LKQ Corporation InvestorPlace
Feb-28-19 04:32PM  Why Monster Beverage, Horizon Pharma, and Guardant Health Jumped Today Motley Fool +32.77%
04:26PM  No. 1 Pharma Skyrockets To 4-Year High On Bullish Results In Eye Disease Investor's Business Daily
02:30PM  Monster Beverage Leads Nasdaq 100; J&J, Coca-Cola, Walmart Prop Up Dow Jones Investor's Business Daily
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOAug 08Sale26.5820,609547,83028,382Aug 12 04:58 PM
Kent JeffSee remarksAug 05Sale23.8411,140265,540107,115Aug 05 04:59 PM
Karnani VikramEVP, Chief Commercial OfficerJul 01Sale25.0213,111327,98057,412Jul 03 04:06 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOFeb 25Sale21.2110,080213,77128,867Feb 25 07:03 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOFeb 05Sale23.158,835204,55928,867Feb 05 04:41 PM
McHugh Miles WSr VP & Princ. Acctg OfficerJan 22Option Exercise12.1916,406199,98999,140Jan 23 04:47 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 26Option Exercise12.1916,406199,98979,346Dec 28 04:50 PM
Walbert Timothy PChairman, President and CEONov 19Option Exercise4.3249,801214,959595,871Nov 21 04:41 PM
Walbert Timothy PChairman, President and CEONov 14Option Exercise7.12408,3472,906,049954,417Nov 16 07:11 PM
Walbert Timothy PChairman, President and CEONov 14Sale21.54408,3478,795,794546,070Nov 16 07:11 PM
open in yahoo | open in reuters | open in google